As we all wearily trawl through the huge mountain of data for ASCO 2017, what stands out – and more importantly – what matters and why?
Before we get into our in-depth coverage based on the tumour type, target and modality landscapes, I wanted to take a moment to highlight five key abstracts that stood out for me as worthy of checking out in more detail once we get to Chicago.
Interestingly, only one of them is from big Pharma!
At least one had some negatives associated with it as we’re not all happy clappy everything is great enthusiasts here at BSB. We do try to be fair minded and objective as possible about data.
So what’s in store and why do these five matter?
To learn about our insights, subscribers can login to read more or you can gain assess via the blue box below…
After several years in the wastelands of cancer research due to lack of significant results and only one product on the market, therapeutic cancer vaccines now look to be back in fashion and are seeing a revival with their inclusion in clinical trials.
One of the reasons behind the resurgence of interest is the advent of checkpoints, and the potential of vaccines in the immuno-oncology space to boost or enhance the immune response.
Their use could not only increase the response to checkpoint inhibitors in people who might otherwise not respond, but in those who obtain some initial response such as a partial response, they could also potentially help achieve a more durable long-term response.
As we continue to ride the wave of cancer immunotherapy on BSB, the cancer vaccine field is suddenly an exciting area to watch.
I’ve long been known as a cancer vaccine sceptic, although recently several approaches in this niche have begun to look rather promising indeed. Here, we highlight and discuss one such company in the field, including an interview with the CEO.
Subscribers can login to read more insights or if you have an interest in immuno-oncology, you can gain access to the interview via the blue box below…
Over the last year or two, we have covered a number of different pathways that are involved with the immune system including CD19 and 20, CTLA–4, PD–1 and PD-L1, IDO1, CD40, OX40, TIGIT, ICOS and others.
Today, it’s the turn of an oncoprotein called NY-ESO–1 that has been garnering quite a bit of attention of late and will also be highly relevant to some upcoming posts and thought leader interviews we have scheduled here on Biotech Strategy Blog. It’s always a good idea to cover the basics first, before exploring the more advanced concepts.
To learn more about our insights, subscribers can log in or you can sign up in the box below.